Allergan News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.02.17	Allergan Launches See America(SM), a Bold Initiative Furthering the Fight Against Preventable Blindness (PR Newswire)
03.02.17	Allergan Declares First Quarterly Cash Dividend of $0.70 Per Ordinary Share (PR Newswire)
03.02.17	Allergan Announces Board Changes - Quick Facts (RTTNews)
03.02.17	Allergan Provides Board and Annual Shareholder Meeting Updates (PR Newswire)
01.02.17	Allergan Successfully Completes LifeCell Acquisition (PR Newswire)
30.01.17	Allergan: FDA Approves SNDA For AVYCAZ To Include Phase III Data - Quick Facts (RTTNews)
27.01.17	Allergan Launches Juvéderm® VOLITE - An Innovative Injectable Treatment Designed to Improve Skin Quality for up to 9 Months (PR Newswire)
26.01.17	Ironwood, Allergan: FDA Approves 72mcg Dose Of Linzess For Adult CIC Patients (RTTNews)
26.01.17	Biotech Stocks Facing FDA Decision In February (RTTNews)
23.01.17	Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists (PR Newswire)
19.01.17	Allergan Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults (PR Newswire)
17.01.17	Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids (PR Newswire)
12.01.17	Allergan to Report Fourth Quarter and Full Year 2016 Earnings and Host Conference Call and Webcast (PR Newswire)
09.01.17	Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds (PR Newswire)
05.01.17	Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference and Provides Preliminary Comments on 2017 Outlook (PR Newswire)
04.01.17	FDA Accepts For Filing Supplemental New Drug Application (sNDA) For LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg (PR Newswire)
04.01.17	Technical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma, and Catalent (PR Newswire)
03.01.17	EQUITY UPDATE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Allergan PLC - AGN (PR Newswire)
03.01.17	Allergan Announces FDA Approval of NATRELLE INSPIRA® SoftTouch Breast Implants (PR Newswire)
24.12.16	Class Action Lawsuit Filed in the United States District Court for the District of New Jersey Against Allergan plc on Behalf of Shareholders - Lead Plaintiff Deadline Remains January 3, 2017 -- AGN (PR Newswire)
22.12.16	Allergan plc Board of Directors Issues Statement on Company's Social Contract with Patients (PR Newswire)
21.12.16	Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference (PR Newswire)
20.12.16	Allergan to Acquire Acelity L.P. Inc.'s LifeCell Corporation for $2.9 Billion (PR Newswire)
19.12.16	Salpeter Gitkin, LLP Informing Investors of Allergan plc of Securities Class Action Lawsuits (PR Newswire)
15.12.16	Allergan Announces Civil Resolution Concluding Federal Investigation into Forest Sales & Marketing Practices (PR Newswire)
15.12.16	Aegon Announces Management Changes (PR Newswire)
15.12.16	Aegon Announces Management Changes (PR Newswire)
08.12.16	Allergan Comments on PTAB Decision Regarding Mylan's Petitions for Inter Partes Review (IPR) of RESTASIS® Patents (PR Newswire)
08.12.16	Aegon Accelerates Execution of Strategy and Increases Expense Savings (PR Newswire)
08.12.16	Aegon Accelerates Execution of Strategy and Increases Expense Savings (PR Newswire)
08.12.16	Aegon Accelerates Execution of Strategy and Increases Expense Savings (PR Newswire)
02.12.16	Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab (PR Newswire)
02.12.16	Allergan Provides Update on Accelerated Share Repurchase (ASR) Program (PR Newswire)
02.12.16	Allergan Announces Settlement of a DELZICOL® (mesalamine) Patent Litigation (PR Newswire)
01.12.16	Technical Reports on Generic Drugs Stocks -- Mylan, Horizon Pharma, Allergan, and Catalent (PR Newswire)
28.11.16	Aegon to Appoint Matthew Rider as CFO (PR Newswire)
28.11.16	Aegon to Appoint Matthew Rider as CFO (PR Newswire)
23.11.16	Allergan PLC Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important Deadline in Class Action filed by Firm - AGN (PR Newswire)
22.11.16	Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease (PR Newswire)
22.11.16	Allergan Receives FDA Clearance for the XEN® Gel Stent, a New Surgical Treatment for Refractory Glaucoma (PR Newswire)
21.11.16	FIBRISTAL®, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment (PR Newswire)
19.11.16	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc of Class Action Lawsuit and Upcoming Deadline - AGN (PR Newswire)
01.10.15	Allergan Receives FDA Approval To Market JUVEDERM ULTRA XC For Lip Augmentation (RTTNews)
25.09.15	Allergan Launches Generic Version Of Janssen's Invega In U.S. - Quick Facts (RTTNews)
11.09.15	Allergan : FDA Oks 3 Extended Release Products Equivalent To Mucinex, Mucinex DM (RTTNews)
31.08.15	Allergan Completes Naurex Acquisition - Quick Facts (RTTNews)
25.08.15	Allergan Recalls Specific Lots Of Ophthalmic Products Due To Particulate Matter (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

09.02.20		Ausblick: Allergan veröffentlicht Zahlen zum vergangenen Quartal
04.10.19		Molecular Partners-Aktie gefragt: Molecular Partners kündigt neue Daten vom Partner Allergan zu Augenmittel an
04.08.19		Ausblick: Allergan stellt Ergebnisse des abgelaufenen Quartals vor
05.05.19		Ausblick: Allergan informiert über die jüngsten Quartalsergebnisse
19.02.18		Molecular Partners: Partner Allergan zieht weitere Option für DARPin-Kandidaten
22.12.17		Novartis erreicht Zwischenerfolg in Patentstreit mit Allergan

09.02.20

Ausblick: Allergan veröffentlicht Zahlen zum vergangenen Quartal

04.10.19

Molecular Partners-Aktie gefragt: Molecular Partners kündigt neue Daten vom Partner Allergan zu Augenmittel an

04.08.19

Ausblick: Allergan stellt Ergebnisse des abgelaufenen Quartals vor

05.05.19

Ausblick: Allergan informiert über die jüngsten Quartalsergebnisse

19.02.18

Molecular Partners: Partner Allergan zieht weitere Option für DARPin-Kandidaten

22.12.17

Novartis erreicht Zwischenerfolg in Patentstreit mit Allergan

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Allergan plc

Aktien Top/Flop

Allergan Peer Group Nachrichten

Meistgelesene Nachrichten